About Us Services Careers FAQ Contact Us 0
Home Pharmaceuticals Immunoglobulins Market Size, Share and Forecast to 2031
Immunoglobulins Market

Immunoglobulins Market Size, Share & Trends Analysis Report By Product (Intravenous Immunoglobulin, Subcutaneous Immunoglobulin, Intramuscular Immunoglobulin), By Applications (Primary Immunodeficiency, Chronic Immune Deficiency Polyradiculoneuropathy, Secondary Immunodeficiency, Immune Thrombocytopenic Purpura, Myasthenia Gravis, Others), By End-User (Hospital and Clinic, Homecare) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Report Code: SRPH54542DR
Last Updated : June 06, 2023
Author : Straits Research
Starting From
USD 2300
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Immunoglobulins Market Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Intravenous Immunoglobulin
        1. By Value
      3. Subcutaneous Immunoglobulin
        1. By Value
      4. Intramuscular Immunoglobulin
        1. By Value
    3. By Applications
      1. Introduction
        1. Applications By Value
      2. Primary Immunodeficiency
        1. By Value
      3. Chronic Immune Deficiency Polyradiculoneuropathy
        1. By Value
      4. Secondary Immunodeficiency
        1. By Value
      5. Immune Thrombocytopenic Purpura
        1. By Value
      6. Myasthenia Gravis
        1. By Value
      7. Others
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Hospital and Clinic
        1. By Value
      3. Homecare
        1. By Value
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Intravenous Immunoglobulin
        1. By Value
      3. Subcutaneous Immunoglobulin
        1. By Value
      4. Intramuscular Immunoglobulin
        1. By Value
    3. By Applications
      1. Introduction
        1. Applications By Value
      2. Primary Immunodeficiency
        1. By Value
      3. Chronic Immune Deficiency Polyradiculoneuropathy
        1. By Value
      4. Secondary Immunodeficiency
        1. By Value
      5. Immune Thrombocytopenic Purpura
        1. By Value
      6. Myasthenia Gravis
        1. By Value
      7. Others
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Hospital and Clinic
        1. By Value
      3. Homecare
        1. By Value
    5. U.S.
      1. By Product
        1. Introduction
          1. Product By Value
        2. Intravenous Immunoglobulin
          1. By Value
        3. Subcutaneous Immunoglobulin
          1. By Value
        4. Intramuscular Immunoglobulin
          1. By Value
      2. By Applications
        1. Introduction
          1. Applications By Value
        2. Primary Immunodeficiency
          1. By Value
        3. Chronic Immune Deficiency Polyradiculoneuropathy
          1. By Value
        4. Secondary Immunodeficiency
          1. By Value
        5. Immune Thrombocytopenic Purpura
          1. By Value
        6. Myasthenia Gravis
          1. By Value
        7. Others
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Hospital and Clinic
          1. By Value
        3. Homecare
          1. By Value
    6. Canada
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Intravenous Immunoglobulin
        1. By Value
      3. Subcutaneous Immunoglobulin
        1. By Value
      4. Intramuscular Immunoglobulin
        1. By Value
    3. By Applications
      1. Introduction
        1. Applications By Value
      2. Primary Immunodeficiency
        1. By Value
      3. Chronic Immune Deficiency Polyradiculoneuropathy
        1. By Value
      4. Secondary Immunodeficiency
        1. By Value
      5. Immune Thrombocytopenic Purpura
        1. By Value
      6. Myasthenia Gravis
        1. By Value
      7. Others
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Hospital and Clinic
        1. By Value
      3. Homecare
        1. By Value
    5. U.K.
      1. By Product
        1. Introduction
          1. Product By Value
        2. Intravenous Immunoglobulin
          1. By Value
        3. Subcutaneous Immunoglobulin
          1. By Value
        4. Intramuscular Immunoglobulin
          1. By Value
      2. By Applications
        1. Introduction
          1. Applications By Value
        2. Primary Immunodeficiency
          1. By Value
        3. Chronic Immune Deficiency Polyradiculoneuropathy
          1. By Value
        4. Secondary Immunodeficiency
          1. By Value
        5. Immune Thrombocytopenic Purpura
          1. By Value
        6. Myasthenia Gravis
          1. By Value
        7. Others
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Hospital and Clinic
          1. By Value
        3. Homecare
          1. By Value
    6. Germany
    7. France
    8. Spain
    9. Italy
    10. Russia
    11. Nordic
    12. Benelux
    13. Rest of Europe
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Intravenous Immunoglobulin
        1. By Value
      3. Subcutaneous Immunoglobulin
        1. By Value
      4. Intramuscular Immunoglobulin
        1. By Value
    3. By Applications
      1. Introduction
        1. Applications By Value
      2. Primary Immunodeficiency
        1. By Value
      3. Chronic Immune Deficiency Polyradiculoneuropathy
        1. By Value
      4. Secondary Immunodeficiency
        1. By Value
      5. Immune Thrombocytopenic Purpura
        1. By Value
      6. Myasthenia Gravis
        1. By Value
      7. Others
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Hospital and Clinic
        1. By Value
      3. Homecare
        1. By Value
    5. China
      1. By Product
        1. Introduction
          1. Product By Value
        2. Intravenous Immunoglobulin
          1. By Value
        3. Subcutaneous Immunoglobulin
          1. By Value
        4. Intramuscular Immunoglobulin
          1. By Value
      2. By Applications
        1. Introduction
          1. Applications By Value
        2. Primary Immunodeficiency
          1. By Value
        3. Chronic Immune Deficiency Polyradiculoneuropathy
          1. By Value
        4. Secondary Immunodeficiency
          1. By Value
        5. Immune Thrombocytopenic Purpura
          1. By Value
        6. Myasthenia Gravis
          1. By Value
        7. Others
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Hospital and Clinic
          1. By Value
        3. Homecare
          1. By Value
    6. Korea
    7. Japan
    8. India
    9. Australia
    10. Taiwan
    11. South East Asia
    12. Rest of Asia-Pacific
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Intravenous Immunoglobulin
        1. By Value
      3. Subcutaneous Immunoglobulin
        1. By Value
      4. Intramuscular Immunoglobulin
        1. By Value
    3. By Applications
      1. Introduction
        1. Applications By Value
      2. Primary Immunodeficiency
        1. By Value
      3. Chronic Immune Deficiency Polyradiculoneuropathy
        1. By Value
      4. Secondary Immunodeficiency
        1. By Value
      5. Immune Thrombocytopenic Purpura
        1. By Value
      6. Myasthenia Gravis
        1. By Value
      7. Others
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Hospital and Clinic
        1. By Value
      3. Homecare
        1. By Value
    5. UAE
      1. By Product
        1. Introduction
          1. Product By Value
        2. Intravenous Immunoglobulin
          1. By Value
        3. Subcutaneous Immunoglobulin
          1. By Value
        4. Intramuscular Immunoglobulin
          1. By Value
      2. By Applications
        1. Introduction
          1. Applications By Value
        2. Primary Immunodeficiency
          1. By Value
        3. Chronic Immune Deficiency Polyradiculoneuropathy
          1. By Value
        4. Secondary Immunodeficiency
          1. By Value
        5. Immune Thrombocytopenic Purpura
          1. By Value
        6. Myasthenia Gravis
          1. By Value
        7. Others
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Hospital and Clinic
          1. By Value
        3. Homecare
          1. By Value
    6. Turkey
    7. Saudi Arabia
    8. South Africa
    9. Egypt
    10. Nigeria
    11. Rest of MEA
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Intravenous Immunoglobulin
        1. By Value
      3. Subcutaneous Immunoglobulin
        1. By Value
      4. Intramuscular Immunoglobulin
        1. By Value
    3. By Applications
      1. Introduction
        1. Applications By Value
      2. Primary Immunodeficiency
        1. By Value
      3. Chronic Immune Deficiency Polyradiculoneuropathy
        1. By Value
      4. Secondary Immunodeficiency
        1. By Value
      5. Immune Thrombocytopenic Purpura
        1. By Value
      6. Myasthenia Gravis
        1. By Value
      7. Others
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Hospital and Clinic
        1. By Value
      3. Homecare
        1. By Value
    5. Brazil
      1. By Product
        1. Introduction
          1. Product By Value
        2. Intravenous Immunoglobulin
          1. By Value
        3. Subcutaneous Immunoglobulin
          1. By Value
        4. Intramuscular Immunoglobulin
          1. By Value
      2. By Applications
        1. Introduction
          1. Applications By Value
        2. Primary Immunodeficiency
          1. By Value
        3. Chronic Immune Deficiency Polyradiculoneuropathy
          1. By Value
        4. Secondary Immunodeficiency
          1. By Value
        5. Immune Thrombocytopenic Purpura
          1. By Value
        6. Myasthenia Gravis
          1. By Value
        7. Others
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Hospital and Clinic
          1. By Value
        3. Homecare
          1. By Value
    6. Mexico
    7. Argentina
    8. Chile
    9. Colombia
    10. Rest of LATAM
    1. Immunoglobulins Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. CSL Limited
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Takeda Pharmaceutical Company Limited
    3. Octapharma AG
    4. Kendrion Biopharma
    5. China Biologic Products Holdings Inc.
    6. Reliance Life Sciences, Biotest AG
    7. LFB S.A.
    8. ADMA Biologics Inc.
    9. Omrix Biopharmaceuticals LTD
    10. Zydus Cadila
    11. Bharat Serums
    12. Vaccines Limited
    13. Grifols S.A.
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
The immunoglobulin market size was valued at USD 13,799.45 million in 2022. It is expected to reach USD 24,446.1 million by 2030, growing at a CAGR of 6.56% during the forecast period (2023–2031). Immunoglobulins are a group of glycoprotein mo
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright . All rights Reserved.